Theravance Biopharma, Inc is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 359 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Theravance Biopharma
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TBPH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Theravance Biopharma stock price (NASDAQ: TBPH)Use our graph to track the performance of TBPH stocks over time.
Theravance Biopharma shares at a glance
|Latest market close||$17.10|
|52-week range||$12.99 - $22.74|
|50-day moving average||$15.24|
|200-day moving average||$18.25|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.05|
Buy Theravance Biopharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Theravance Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Theravance Biopharma price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||18.67%|
|3 months (2021-04-30)||-13.37%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Theravance Biopharma financials
|Revenue TTM||$66.3 million|
|Gross profit TTM||$-189,096,000|
|Return on assets TTM||-39.41%|
|Return on equity TTM||0%|
|Market capitalisation||$947.2 million|
TTM: trailing 12 months
Shorting Theravance Biopharma shares
There are currently 2.9 million Theravance Biopharma shares held short by investors – that's known as Theravance Biopharma's "short interest". This figure is 1.5% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Theravance Biopharma shares can be evaluated.
Theravance Biopharma's "short interest ratio" (SIR)
Theravance Biopharma's "short interest ratio" (SIR) is the quantity of Theravance Biopharma shares currently shorted divided by the average quantity of Theravance Biopharma shares traded daily (recently around 546686.84210526). Theravance Biopharma's SIR currently stands at 5.32. In other words for every 100,000 Theravance Biopharma shares traded daily on the market, roughly 5320 shares are currently held short.
However Theravance Biopharma's short interest can also be evaluated against the total number of Theravance Biopharma shares, or, against the total number of tradable Theravance Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theravance Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Theravance Biopharma shares in existence, roughly 40 shares are currently held short) or 0.0748% of the tradable shares (for every 100,000 tradable Theravance Biopharma shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Theravance Biopharma.
Find out more about how you can short Theravance Biopharma stock.
Theravance Biopharma share dividends
We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.
Theravance Biopharma share price volatility
Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $12.99 up to $22.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.8852. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).
Theravance Biopharma overview
Theravance Biopharma, Inc. , a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc.
Theravance Biopharma in the news
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Frequently asked questionsWhat percentage of Theravance Biopharma is owned by insiders or institutions?
Currently 17.105% of Theravance Biopharma shares are held by insiders and 76.895% by institutions. How many people work for Theravance Biopharma?
Latest data suggests 359 work at Theravance Biopharma. When does the fiscal year end for Theravance Biopharma?
Theravance Biopharma's fiscal year ends in December. Where is Theravance Biopharma based?
Theravance Biopharma's address is: Ugland House, George Town, Cayman Islands, KY1-1104 What is Theravance Biopharma's ISIN number?
Theravance Biopharma's international securities identification number is: KYG8807B1068 What is Theravance Biopharma's CUSIP number?
Theravance Biopharma's Committee on Uniform Securities Identification Procedures number is: G8807B106
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert